Faithward Advisors LLC Buys New Position in Charles River Laboratories International, Inc. $CRL

Faithward Advisors LLC bought a new stake in Charles River Laboratories International, Inc. (NYSE:CRL) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 7,379 shares of the medical research company’s stock, valued at approximately $1,472,000.

Other institutional investors have also recently added to or reduced their stakes in the company. Massachusetts Financial Services Co. MA acquired a new position in shares of Charles River Laboratories International during the 4th quarter valued at about $176,478,000. Victory Capital Management Inc. increased its stake in shares of Charles River Laboratories International by 9,938.8% during the 4th quarter. Victory Capital Management Inc. now owns 691,474 shares of the medical research company’s stock valued at $137,935,000 after acquiring an additional 684,586 shares during the last quarter. Ameriprise Financial Inc. increased its stake in shares of Charles River Laboratories International by 1,491.1% during the 3rd quarter. Ameriprise Financial Inc. now owns 613,604 shares of the medical research company’s stock valued at $96,005,000 after acquiring an additional 575,039 shares during the last quarter. National Bank of Canada FI increased its stake in shares of Charles River Laboratories International by 117.7% during the 3rd quarter. National Bank of Canada FI now owns 946,769 shares of the medical research company’s stock valued at $148,131,000 after acquiring an additional 511,901 shares during the last quarter. Finally, Norges Bank acquired a new position in shares of Charles River Laboratories International during the 4th quarter valued at about $96,765,000. Institutional investors and hedge funds own 98.91% of the company’s stock.

Charles River Laboratories International Stock Up 0.7%

Shares of NYSE:CRL opened at $188.74 on Tuesday. The company has a debt-to-equity ratio of 0.90, a quick ratio of 1.03 and a current ratio of 1.36. Charles River Laboratories International, Inc. has a 1 year low of $143.06 and a 1 year high of $228.88. The stock has a market capitalization of $9.09 billion, a P/E ratio of -50.20, a PEG ratio of 2.14 and a beta of 1.46. The stock has a 50-day simple moving average of $173.80 and a 200-day simple moving average of $182.57.

Charles River Laboratories International (NYSE:CRL) last issued its earnings results on Thursday, May 7th. The medical research company reported $2.06 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.96 by $0.10. Charles River Laboratories International had a positive return on equity of 15.36% and a negative net margin of 4.59%.The business had revenue of $995.83 million during the quarter, compared to analysts’ expectations of $977.46 million. During the same quarter in the previous year, the business earned $2.34 EPS. The company’s revenue for the quarter was up 1.2% on a year-over-year basis. Charles River Laboratories International has set its FY 2026 guidance at 10.800-11.300 EPS. Equities analysts forecast that Charles River Laboratories International, Inc. will post 11.04 earnings per share for the current year.

Analysts Set New Price Targets

CRL has been the subject of a number of research analyst reports. Barclays upped their price objective on shares of Charles River Laboratories International from $210.00 to $220.00 and gave the company an “overweight” rating in a research note on Friday, May 8th. Evercore reaffirmed an “outperform” rating and set a $220.00 price objective on shares of Charles River Laboratories International in a research note on Friday, May 8th. Robert W. Baird set a $213.00 price objective on shares of Charles River Laboratories International in a research note on Friday, May 8th. JPMorgan Chase & Co. dropped their price objective on shares of Charles River Laboratories International from $165.00 to $160.00 and set a “neutral” rating for the company in a research note on Monday, April 13th. Finally, UBS Group upped their price objective on shares of Charles River Laboratories International from $170.00 to $175.00 and gave the company a “neutral” rating in a research note on Wednesday, February 25th. Eleven research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Charles River Laboratories International presently has a consensus rating of “Moderate Buy” and an average price target of $208.50.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.